Obiltoxaximab

Paul G. Auwaerter, M.D., Kathryn Dzintars, PharmD, BCPS

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Treatment of inhalational anthrax due to Bacillus anthracis (in combination with antibacterial drugs)
  • Prevention of inhalational anthrax when alternative agents are unavailable

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.